BRPI0408996A - saia de inibidores tricìclicos de poli(adpp-ribose) polimerases - Google Patents
saia de inibidores tricìclicos de poli(adpp-ribose) polimerasesInfo
- Publication number
- BRPI0408996A BRPI0408996A BRPI0408996-0A BRPI0408996A BRPI0408996A BR PI0408996 A BRPI0408996 A BR PI0408996A BR PI0408996 A BRPI0408996 A BR PI0408996A BR PI0408996 A BRPI0408996 A BR PI0408996A
- Authority
- BR
- Brazil
- Prior art keywords
- poly
- tricyclic
- adpp
- ribose
- skirt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
"SAIS DE INIBIDORES TRICìCLICOS DE POLI(ADPRIBOSE) POLIMERASES". A presente invenção refere-se aos sais farmaceuticamente aceitáveis de compostos de fórmula (I) que são inibidores da poli(ADP-ribosil)transferase (PARP), e que são úteis como terapêutica no tratamento de cânceres e melhoria dos efeitos de acidente vascular cerebral, traumatismo craniano e doença neurodegenerativa. Como terapêutica do câncer, os compostos da invenção podem ser utilizados, por exemplo, em combinação com agentes citotóxicos e/ou radiação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45943303P | 2003-03-31 | 2003-03-31 | |
PCT/IB2004/000915 WO2004087713A1 (en) | 2003-03-31 | 2004-03-19 | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0408996A true BRPI0408996A (pt) | 2006-03-28 |
Family
ID=33131884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0408996-0A BRPI0408996A (pt) | 2003-03-31 | 2004-03-19 | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases |
Country Status (12)
Country | Link |
---|---|
US (1) | US20040248879A1 (pt) |
EP (1) | EP1611137A1 (pt) |
JP (1) | JP2006522088A (pt) |
AR (1) | AR043950A1 (pt) |
BR (1) | BRPI0408996A (pt) |
CA (1) | CA2520997A1 (pt) |
MX (1) | MXPA05010563A (pt) |
NL (1) | NL1025842C2 (pt) |
PA (1) | PA8598801A1 (pt) |
TW (1) | TW200424206A (pt) |
UY (1) | UY28245A1 (pt) |
WO (1) | WO2004087713A1 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7531530B2 (en) | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
CA2580833C (en) | 2004-09-22 | 2010-12-21 | Pfizer, Inc. | Method of preparing poly(adp-ribose) polymerases inhibitors |
CN101133061B (zh) * | 2004-09-22 | 2011-09-07 | 辉瑞有限公司 | 8-氟-2-{4-[(甲基氨基)甲基]苯基}-1,3,4,5-四氢-6H-氮杂卓并[5,4,3-cd]吲哚-6-酮的磷酸盐的多晶型物和非晶物 |
KR20070046183A (ko) * | 2004-09-22 | 2007-05-02 | 화이자 인코포레이티드 | 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는치료 배합물 |
ATE551345T1 (de) | 2004-09-22 | 2012-04-15 | Pfizer | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on |
BRPI0613783A2 (pt) | 2005-07-18 | 2011-02-01 | Bipar Sciences Inc | tratamento de cáncer |
SI2338487T1 (sl) * | 2006-01-17 | 2014-01-31 | Abbott Laboratories | Kombinacijska terapija z inhibitorji PARP |
AU2007292387A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
AU2007292306A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
AU2008321128A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
EP3150610B1 (en) * | 2010-02-12 | 2019-07-31 | Pfizer Inc | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
HUE052930T2 (hu) * | 2013-04-09 | 2021-05-28 | Univ Illinois | DNQ vagy DNQ-87 alkalmazása PARP1-inhibitorral kombinációban rák kezelésére |
WO2016028689A1 (en) | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | High dosage strength tablets of rucaparib |
CN104592232A (zh) * | 2015-03-02 | 2015-05-06 | 中国药科大学 | 8,9-二氢-2,4,7,9a-四氮杂苯并薁-6(7H)-酮类衍生物 |
DK3594343T3 (da) | 2015-07-23 | 2021-06-28 | Inst Curie | Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
EP3534957A1 (en) | 2016-11-02 | 2019-09-11 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
WO2018140377A1 (en) * | 2017-01-24 | 2018-08-02 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
US20200129476A1 (en) | 2017-04-28 | 2020-04-30 | Akribes Biomedical Gmbh | PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing |
EP3704124A1 (en) * | 2017-11-03 | 2020-09-09 | Sandoz AG | Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor |
PE20211305A1 (es) | 2018-01-05 | 2021-07-20 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas |
WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
KR20220051332A (ko) | 2019-07-10 | 2022-04-26 | 싸이브렉사 3, 인크. | 치료제로서의 미세소관 표적화제의 펩티드 접합체 |
CN114341162A (zh) | 2019-07-10 | 2022-04-12 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
WO2021018298A1 (zh) * | 2019-08-01 | 2021-02-04 | 南京明德新药研发有限公司 | 作为parp抑制剂吲哚并七元酰肟化合物 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4100125A1 (en) | 2020-02-03 | 2022-12-14 | Sandoz AG | Polymorph of rucaparib mesylate |
CN115485271A (zh) | 2020-04-28 | 2022-12-16 | 理森制药股份公司 | 用作聚(adp-核糖)聚合酶(parp)抑制剂的新型化合物 |
WO2022015557A1 (en) | 2020-07-14 | 2022-01-20 | Assia Chemical Industries Ltd | Solid state forms of rucaparib salts |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
CN117321044A (zh) | 2021-04-08 | 2023-12-29 | 理森制药股份公司 | 聚(adp-核糖)聚合酶抑制剂 |
WO2023137060A1 (en) | 2022-01-11 | 2023-07-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3883590A (en) * | 1971-06-01 | 1975-05-13 | Universal Oil Prod Co | Preparation of n-alkylarylcarboxamides |
DE2322434A1 (de) * | 1973-05-04 | 1974-11-21 | Bayer Ag | 2-trifluormethylimino-1,3-dithioloeckige klammer auf 4,5-b eckige klammer zu -chinoxaline, verfahren zu ihrer herstellung, sowie ihre verwendung als insektizide, akarizide und fungizide |
US4033960A (en) * | 1973-07-31 | 1977-07-05 | Bayer Aktiengesellschaft | 2-Mercaptoquinoxaline-di-N-oxide products and a method for their preparation |
US3950343A (en) * | 1973-11-06 | 1976-04-13 | Ayerst, Mckenna And Harrison Ltd. | Pyrroloisoquinoline derivatives |
US3978066A (en) * | 1973-11-06 | 1976-08-31 | Ayerst, Mckenna And Harrison Ltd. | Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives |
US3900477A (en) * | 1973-11-06 | 1975-08-19 | Ayerst Mckenna & Harrison | 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives |
US5215738A (en) * | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
US4910193A (en) * | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
GB9117987D0 (en) * | 1991-08-20 | 1991-10-09 | Ici Plc | Heterocyclic compounds |
US5342946A (en) * | 1992-12-02 | 1994-08-30 | Guilford Pharmaceuticals Inc. | Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors |
US5572143A (en) * | 1993-10-19 | 1996-11-05 | Mac Tools, Inc. | Circuit testing device |
US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
JPH08111047A (ja) * | 1994-10-12 | 1996-04-30 | Hitachi Ltd | 磁気記録再生装置 |
US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
US5756548A (en) * | 1995-04-03 | 1998-05-26 | Centaur Pharmaceuticals, Inc. | Acetamidobenzamide compounds for neurodegenerative disorders |
US5659082A (en) * | 1995-04-03 | 1997-08-19 | Centaur Pharmaceuticals, Inc. | Nitro- and aminobenzamide compounds for neurodegenerative disorders |
SK287338B6 (sk) * | 1999-01-11 | 2010-07-07 | Agouron Pharmaceuticals, Inc. | Tricyklická zlúčenina, jej použitie a farmaceutická kompozícia s jej obsahom |
MXPA02011218A (es) * | 2000-05-15 | 2004-08-19 | Celgene Corp | Composiciones y metodos para el tratamiento de cancer. |
US7531530B2 (en) * | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
ATE551345T1 (de) * | 2004-09-22 | 2012-04-15 | Pfizer | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on |
-
2004
- 2004-03-19 WO PCT/IB2004/000915 patent/WO2004087713A1/en not_active Application Discontinuation
- 2004-03-19 MX MXPA05010563A patent/MXPA05010563A/es unknown
- 2004-03-19 JP JP2006506393A patent/JP2006522088A/ja active Pending
- 2004-03-19 CA CA002520997A patent/CA2520997A1/en not_active Abandoned
- 2004-03-19 BR BRPI0408996-0A patent/BRPI0408996A/pt not_active IP Right Cessation
- 2004-03-19 EP EP04721967A patent/EP1611137A1/en not_active Withdrawn
- 2004-03-25 TW TW093108164A patent/TW200424206A/zh unknown
- 2004-03-25 PA PA20048598801A patent/PA8598801A1/es unknown
- 2004-03-29 UY UY28245A patent/UY28245A1/es not_active Application Discontinuation
- 2004-03-29 US US10/811,513 patent/US20040248879A1/en not_active Abandoned
- 2004-03-29 NL NL1025842A patent/NL1025842C2/nl not_active IP Right Cessation
- 2004-03-29 AR ARP040101037A patent/AR043950A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2004087713A1 (en) | 2004-10-14 |
JP2006522088A (ja) | 2006-09-28 |
CA2520997A1 (en) | 2004-10-14 |
US20040248879A1 (en) | 2004-12-09 |
NL1025842A1 (nl) | 2004-10-01 |
PA8598801A1 (es) | 2004-11-26 |
AR043950A1 (es) | 2005-08-17 |
UY28245A1 (es) | 2004-11-08 |
NL1025842C2 (nl) | 2005-11-15 |
EP1611137A1 (en) | 2006-01-04 |
TW200424206A (en) | 2004-11-16 |
WO2004087713A8 (en) | 2005-01-20 |
MXPA05010563A (es) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0408996A (pt) | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases | |
TR200102005T2 (tr) | Poli(adp-ribaz) polimerazların trisiklik inhibitörleri. | |
BR0015051A (pt) | Compostos inibidores tricìclicos de poli(adp-ribose) polimerase, seu sal farmaceuticamente aceitável, pró-droga, metabólito ativo, ou solvato, composição farmacêutica, método de inibição da atividade de parp de uma enzima e método de inibição da atividade de enzima parp em tecido de mamìfero | |
BR0208373A (pt) | Inibidores da tirosina cinase | |
RS20050522A (en) | Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation | |
BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
BRPI0306993B8 (pt) | polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível | |
ATE538103T1 (de) | Chinazolinonverbindungen als antikrebsmittel | |
BRPI0409366A (pt) | compostos de pirimido | |
DE602004025698D1 (de) | PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS | |
BR0307819A (pt) | Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais | |
CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
BRPI0410913A (pt) | benzotiofenos substituìdos com cicloalquil e heterocicloalquil como agentes terapêuticos | |
BR0207487A (pt) | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona | |
BRPI0411098A (pt) | benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos | |
BRPI0411122A (pt) | pirazol[3,4-b]piridin-6-onas como inibidores gsk-3 | |
MX2019010898A (es) | Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cancer. | |
BRPI0411092A (pt) | benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos | |
BRPI0413384A (pt) | inibidores da proteìna farnesil transferase como agentes antitumores | |
BRPI0414700A (pt) | 6-[(substituìdo)fenil]triazolopirimidinas como agentes anti-cáncer | |
BRPI0514187A (pt) | composto, e, droga preventiva ou uma droga terapêutica | |
BR0114276A (pt) | Derivados de benzodiazepina ou sais destes farmaceuticamente aceitáveis, agente para inibir o fator x de coagulação do sangue ativado, composição farmacêutica, e, inibidor da coagulação sanguìnea ou um agente para prevenir ou tratar a trombose ou o embolismo | |
BR0111813A (pt) | Composições farmacêuticas e produto compreendendo derivados de distamicina acriloìla, e inibidores de topoisomerase i e ii, e seu uso | |
NO20026032D0 (no) | Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer | |
BRPI0414171A (pt) | benzo[b]tiofenos halossubstituìdos com atividade inibidora de pi3k como agentes terapêuticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |